2 July 2024 · 1 min read
PharmaTech is increasingly becoming a category on its own, with PitchBook's Kazi Y. Helal, PhD e...
PharmaTech is increasingly becoming a category on its own, with PitchBook launching a dedicated research report and Q1 2024 seeing $749 million in funding across 39 deals. I think it's worth examining how they define the category, given the interesting mix of CDMO/CMO activities and AI enablement they cluster together.
Author
Last updated
6 May 2026
PharmaTech is increasingly becoming a category on its own, with PitchBook's Kazi Y. Helal, PhD even launching a dedicated research report. Notably, Q1 2024 saw $749 million in funding across 39 deals.
It is worth having a look at their definition of this category however, as they cluster together an interesting mix of CDMO/CMO activities, around areas like nucleic acid chemistry and Cell&Gene Therapy support, and only partially the latest evolutions in AI enablement of the pharma value chain.